|Bid||0.4950 x 0|
|Ask||0.5200 x 0|
|Day's Range||0.5000 - 0.5200|
|52 Week Range||0.4350 - 1.2300|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTC PINK: MPXOF) is pleased to announce that it is extending its partnership with Volteface, a UK-based cross party organization that informs the public debate around drugs through excellence in policy, research and advocacy. Since starting out in 2016, with the aim of providing a new focus on drug policy reform, Volteface has evolved into an important and influential organization. During this time, the United Kingdom has seen significant developments in cannabis reform, most notably the legalization of medical cannabis in November 2018.
OTC PINK: MPXOF) is pleased to announce that it has entered into an agreement with First Growth Holdings (Pty) Ltd. ("First Growth") which provides the basis for MPXI and First Growth to enter into a series of agreements through which MPXI intends to acquire a 51% interest in First Growth, subject to the completion of due diligence as well as definitive documentation. First Growth is applying under the Medicines and Related Substances Act, No. 101 of 1965 for a license to cultivate, manufacture and export cannabis from the Sonop Farm, which is located in the traditional wine-growing region of Stellenbosch in South Africa's Western Cape.
OTC PINK: MPXOF) is pleased to announce the addition of Dr. Charles Akle to its medical advisory board. The UK-based Dr. Akle is a leading world authority in the fields of immunology and cancer treatment, renowned for over 30 years of pioneering work in clinical surgery and developing products in the biotech industry. "His experience navigating emerging medical markets and working with the various regulatory bodies is unique and invaluable as we look to further develop and introduce our products in a responsible and sustainable manner," said W. Scott Boyes, Chairman, President and CEO of MPXI.
NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES ...
TORONTO, ONTARIO / ACCESSWIRE / May 23, 2019 / MPX International Corporation ("MPX International", "MPXI" or the "Company") (CSE: MPXI; OTC PINK: MPXOF) is pleased to announce ...
OTC:MPXOF) is pleased to announce that it has completed the previously announced acquisition of all of the outstanding shares of HolyWorld SA ("HolyWeed") from Romain Gruner, Bernard Rappaz and Laurent Rappaport (the "Shareholders") for a total purchase price of CHF10,000,000 (CDN$13,384,000 calculated using a deemed exchange rate of CDN$1.34 for each CHF 1.00) (the "Purchase Price"). Pursuant to the terms of the definitive agreement, MPXI satisfied the Purchase Price through the issuance of 25,252,830 common shares of MPXI (the "MPXI Shares") to the Shareholders at price of CDN$0.53 per MPXI Share.
OTC PINK: MPXOF) is pleased to announce that MPXI Malta Property Ltd. (''MPXI Malta''), a Maltese-company owned by MPX International (80%) and Malta-based Bortex Group (''Bortex'') (20%) has entered into a definitive agreement to purchase all outstanding shares of Alphafarma Operations Ltd. (''Alphafarma'') from Alpha Farma Limited (the ''Vendor''). Additionally, MPXI Malta has been awarded a letter of intent (the ''LOI'') from Malta Enterprise, the economic development agency for the Republic of Malta, a member of the European Union, to receive a license to import, extract, produce finished products and distribute cannabis and cannabis derivatives (the ''License'') for medicinal use in Malta and export to certain international markets, such as the European Union.
OTC PINK: MPXOF) is pleased to announce that it has entered into a definitive agreement to purchase all outstanding shares of HolyWorld SA ("HolyWeed") from Romain Gruner, Bernard Rappaz and Laurent Rappaport (the "Shareholders"). This acquisition represents a major step in MPXI's expansion strategy, adding a highly recognized brand to its portfolio, as well as one of the largest Western European outdoor cultivators of high-CBD flowers. Pursuant to the terms of the Purchase Agreement, MPXI will acquire all of the HolyWeed Shares for a total purchase price of CHF10,000,000 (CDN$13,384,000 calculated using a deemed exchange rate of CDN$1.34 for each CHF1.00 for the purposes of this resolution which number shall be adjusted upwards or downwards to the extent necessary using the exchange rate posted at the close of business by the Bank of Canada five (5) days prior to closing) through the issuance of common shares of MPXI (the "MPXI Shares") at price of CDN$0.53 per MPXI Share.
ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS. TORONTO, ON / ACCESSWIRE / March 25, 2019 / MPX International Corporation (the ''Company'' or ''MPX'') (CSE: MPXI) is pleased to announce that it has successfully closed its previously announced non-brokered private placement offering (the ''Offering'') of units (the ''Units'') of the Company. Each Unit issued in the Offering consists of one common share (''Common Share'') in the capital of the Company and one Common Share purchase warrant (''Warrant'').
NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION.
MPX International Corporation (“MPX International” or the “Company”) (CSE:MPXI) announces that Canveda Inc. (“Canveda”), a wholly-owned subsidiary of the Company, received its sale for medical purposes and standard processing licences effective as of February 22, 2019 for its facility in Peterborough, Ontario. The licence will allow Canveda, conditional upon Health Canada’s final pre-sales inspection, to develop its medical patient and product strategy and to commence selling their own products directly to registered patients for medical purposes. In the mean time, Canveda will continue selling dried flower products to other Licenced Producers with medical sales licences.
If, at any time after 12 months following the Closing Date, the volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (“CSE”) over any fifteen (15) consecutive trading day period is at least C$2.00, the Company will have the right to accelerate the expiry date of the Warrants to a date that is thirty (30) calendar days after the date on which the Company issues a press release announcing the accelerated expiry date. MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient. This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts.
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2019) - MPX International Corporation (CSE: MPXI) is one of the latest new listing on the Canadian Securities Exchange. The Toronto-based cannabis company is focused on leveraging industry its leading MPX and Salus brands and know-how acquired from its former US operations, to access the burgeoning international cannabis markets, initially the United Kingdom, the European Union and Australia.InvestmentPitch Media has produced a "video" which provides additional ...